Glubio Therapeutics’ GLB-005 (a WIZ molecular glue degrader) was added to China’s Center for Drug Evaluation Patient-Centered Action for Rare Diseases Encouragement (CARE) plan. The inclusion places the program within a CDE framework intended to support the development of rare disease therapies. The update signals that regulators in China are prioritizing novel development pathways for rare conditions, potentially affecting sponsor planning around clinical data generation and review trajectory. For GLB-005, being part of CARE provides a regulatory-aligned signal as it continues toward later clinical steps. It also highlights how patient-focused programs are increasingly used to influence how companies structure evidence packages for rare disease drug applications in China.